Sort
89,613 grants matching “depression”
Novel Treatment Targets For Affective Disorders Through Cross-Species Investigation of Approach/Avoidance Decision Making
$3,174,635Diego A. Pizzagalli · Mclean Hospital · P50 · FY2021 · MH
Evaluation of psilocybin as an adjunctive treatment for opioid use disorder in methadone-maintained patients who continue to use illicit opioids
$3,172,763Michael Parks Bogenschutz · New York University School Of Medicine · UG3 · FY2025 · DA
Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD)
$3,171,989Kimford J Meador · Emory University · U01 · FY2016 · NS
Alzheimer's Disease Research Center
$3,171,322Thomas M Wisniewski · New York University School Of Medicine · P30 · FY2023 · AG
Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD)
$3,171,312Kimford J Meador · Emory University · U01 · FY2012 · NS
Integrative genetics of behavior with high throughput technologies
$3,169,828David Goldman · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2014 · AA
Novel Treatment Targets For Affective Disorders Through Cross-Species Investigation of Approach/Avoidance Decision Making
$3,167,713Diego A. Pizzagalli · Mclean Hospital · P50 · FY2022 · MH
Clinical Evaluation of PET Radiotracers
$3,163,585Robert Innis · National Institute Of Mental Health · ZIA · FY2014 · MH
Advancing Targeted Therapies for Cushing's Disease Using Pituitary Neuroendocrine Tumor Organoids
$3,162,826Yana Zavros · University Of Georgia · R01 · FY2025 · DK
Novel Treatment Targets For Affective Disorders Through Cross-Species Investigation of Approach/Avoidance Decision Making
$3,162,041Diego A. Pizzagalli · Mclean Hospital · P50 · FY2023 · MH
Mechanisms Of Synaptic Plasticity In The Adult And Developing Nervous System
$3,161,057Serena M Dudek · National Institute Of Environmental Health Sciences · ZIA · FY2017 · ES
Suicide Care Research Center
$3,157,410Katherine Anne Comtois · University Of Washington · P50 · FY2025 · MH
MBRS-SCORE Program at UPR-Medical Sciences Campus
$3,155,975University Of Puerto Rico Med Sciences · S06 · FY2005 · GM
International evaluation of modifiable social determinants of health on COVID-related mental health outcomes
$3,155,102Jordan W Smoller · Massachusetts General Hospital · RF1 · FY2023 · MH
MBRS-SCORE Program at UPR-Medical Sciences Campus
$3,154,877University Of Puerto Rico Med Sciences · S06 · FY2004 · GM
Novel Treatment Targets For Affective Disorders Through Cross-Species Investigation of Approach/Avoidance Decision Making
$3,151,881Diego A. Pizzagalli · Mclean Hospital · P50 · FY2024 · MH
The Pathophysiology and Treatment of Children with Severe Irritability
$3,148,897Ellen Leibenluft · National Institute Of Mental Health · ZIA · FY2019 · MH
Biased Mu-Opioid Receptor Analgesics to Prevent Overdose and Opioid Use Disorders
$3,146,950Lawrence C Kuo · Mebias Discovery, Inc. · UH3 · FY2020 · DA
CLINICAL CENTER FOR MONITORING HEALTH IN WTC RESPONDERS
$3,146,697Iris Greenberg Udasin · Univ Of Med/Dent Nj-R W Johnson Med Sch · U10 · FY2010 · OH
Multimodal Fetal and Placental Imaging and Biomarkers of Clinical Outcomes in Opioid Use Disorder
$3,145,305Rupa Radhakrishnan · Indiana University Indianapolis · R01 · FY2023 · DA
PHARMACOGENETICS OF MEMBRANE TRANSPORTERS
$3,145,199University Of California San Francisco · U01 · FY2000 · GM
Pharmacogenetics of Phase II Drug Metabolizing Enzymes
$3,141,483Richard M Weinshilboum · Mayo Clinic Rochester · U19 · FY2014 · GM
Adverse Health Outcomes From Extreme Heat, Air Pollution, and Medications in Low-Income Pregnant Women and Their Offspring
$3,140,397Soko Setoguchi-Iwata · Rutgers Biomedical And Health Sciences · R01 · FY2025 · HD
Mouse models of stress disorders and addiction
$3,139,828Andrew Holmes · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2024 · AA
Clinical Development of SBS-147: First-in-class Oral Arylepoxamide Agonist for Pain
$3,138,031Judy Ashworth · Sparian Biosciences, Inc. · UG3 · FY2025 · DA